sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Pulmonary Drug Delivery Systems Market Size, Share & Trends Analysis - Global opportunity analysis and industry forecast 2030

Pulmonary Drug Delivery Systems Market Size, Share & Trends Analysis...

Home / Categories / Healthcare
Pulmonary Drug Delivery Systems Market Size, Share & Trends Analysis - Global opportunity analysis and industry forecast 2030
Pulmonary Drug Delivery Systems Market...
Report Code
RO14/128/1631

Publish Date
05/Dec/2021

Pages
190
PRICE
$ 4570/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 5450/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 7695/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..

The global pulmonary drug delivery systems market was US$ 53267.55 in 2021. The global pulmonary drug delivery systems market is forecast to reach US$ 91,128.65 million by 2030, growing at a compound annual growth rate (CAGR) of 7% during the forecast period from 2022 to 2030. 

"Targeted drug delivery" means to direct drugs toward the target site. Pulmonary drug delivery is a  targeted drug delivery system that delivers the drug moiety to the lower respiratory tract. As the name suggests, pulmonary drug delivery refers to the process of administering drugs through the lungs. Inhalation is a more effective method of administering drugs for asthma and chronic obstructive pulmonary disease. The delivery of pulmonary medicines offers immediate relief from asthmatic attacks and acute bronchitis. Pulmonary aerosols are a particular type of device that delivers drugs to the lungs.

 Factors Influencing Market Growth

  • Increasing air pollution, a rise in prevalence of lung diseases such as asthma and chronic obstructive pulmonary disease, an increase in hospitals and diagnostic centers, and increased funding for pulmonary treatment drive the global pulmonary drug delivery systems market. 
  • Developments in pulmonary drug delivery systems are forecast to contribute to the market's growth. For example, in October 2018, Philips, a global leader in health technology, launched InnoSpire Go, a portable nebulizer that delivers medication in just four minutes, despite being small and lightweight.
  • The increase in awareness of pulmonary diseases and the growing number of hospitals and diagnostic centers are forecast to pose lucrative opportunities for growth in the global pulmonary drug delivery systems market during the forecast period.
  • The high cost of pulmonary drug delivery system devices and inaccurate diagnosis of respiratory diseases may slow down the global market growth during the forecast period.

Impact Analysis of COVID-19

The outbreak of COVID-19 had a positive impact on the global pulmonary drug delivery systems market. People with Chronic Obstructive Pulmonary Diseases and asthma were at higher risk of death from COVID-19. Globally, the COVID-19 pandemic has put tremendous pressure on healthcare systems, which has led to the need for diagnostic tools & treatment facilities. Many clinics and hospitals throughout the world restructured their operations to accommodate the increasing number of patients diagnosed with COVID-19. More hospitals had increased the number of diagnoses. The COVID-19 pandemic may have altered a patient's response to respiratory symptoms, making them less likely to seek treatment. As a result, the global market has grown significantly.

Regional Insights

In 2021, North America dominated the pulmonary drug delivery systems market and is forecast to continue dominating during the forecast period. The increasing prevalence of pulmonary diseases, the presence of key players in the manufacturing and development of pulmonary disease drugs, the growth of hospitals and diagnostic centers, and government initiatives to improve the treatment of pulmonary disease in the region all contribute to this growth.

Asia-Pacific is forecast to grow at the fastest CAGR during the forecast period. Due to the increasing prevalence of pulmonary diseases, the need for pulmonary drug delivery, and the development of different healthcare foundations in the region.

Leading Competitors

The leading prominent companies profile in the global pulmonary drug delivery systems market are:

  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • Koninklijke Philips N.V.
  • 3M company
  • Janssen (Johnson & Johnson)
  • Clement Clarke International
  • Briggs Healthcare
  • Aerogen
  • Other Prominent Players

Scope of the Report

The global pulmonary drug delivery systems market segmentation focuses on Product, Application, Distribution Channel, and Region.

Segmentation based on Product

  • Dry powder inhaler
  • Single-dose inhaler
  • Multi-dose inhaler
  • Metered-dose inhaler
  • Manually-Actuated Pressurized Inhaler
  • Breath-Actuated Pressurized Inhaler
  • Nebulizer
  • Jet Nebulizer
  • Ultrasonic Wave Nebulizer
  • Vibrating Mesh Nebulizer

Segmentation based on Application

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Cystic Fibrosis
  • Others

Segmentation based on Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • E-commerce

Segmentation based on Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA
  • South America
  • Brazil
  • Argentina
  • Rest of South America

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com